With the rapid advancement of innovative drug development, cardiovascular safety assessment has become a critical component of nonclinical safety evaluation and an essential consideration throughout drug development and regulatory submission. However, the industry continues to face significant challenges, including limited assessment sensitivity, invasive evaluation methods, insufficient capability for longitudinal monitoring, poor cross-species data translatability, and variability in study outcomes. These limitations can hinder the accurate identification of potential cardiovascular liabilities and complicate efforts to meet increasingly stringent regulatory expectations for drug safety evaluation.

To address these challenges, echocardiography has emerged as a widely adopted and highly valuable tool for cardiovascular safety assessment due to its noninvasive nature, real-time imaging capabilities, and ability to support repeated longitudinal evaluations. Leveraging this technology, InnoStar has established a comprehensive ultrasound imaging evaluation platform spanning multiple laboratory animal species. Supported by years of experience and a robust foundation of standardized preclinical data, the platform enables reliable, precise, and regulatory-compliant cardiovascular assessments, providing integrated solutions for nonclinical cardiovascular safety evaluation in drug development.

01

Cardiovascular Safety Assessment: A Critical Tool in Nonclinical Evaluation

In toxicology and safety assessment, cardiac imaging plays a vital role in detecting potential cardiovascular liabilities associated with investigational drugs. Among available imaging modalities, echocardiography has become an indispensable tool due to its unique ability to provide comprehensive structural and functional cardiac assessments.

Key advantages of echocardiography include:

• Noninvasive, real-time visualization of cardiac chambers, myocardial motion, and intracardiac blood flow
• Direct assessment of cardiac valve morphology and function, enabling accurate evaluation of valvular and myocardial abnormalities
• Generation of quantitative and highly interpretable endpoints that support robust cardiovascular safety evaluation throughout drug development

Within nonclinical safety assessment programs, echocardiography is widely applied across the entire preclinical development process. Whether in general toxicology studies, repeat-dose toxicity assessments, or dedicated cardiovascular safety evaluations, reliable data on cardiac structure and function are essential for understanding potential drug-related effects. InnoStar’s continued investment in echocardiography capabilities reflects our long-standing commitment to meeting these critical scientific and regulatory requirements.

02

Comprehensive Multi-Species Coverage for Nonclinical Safety Assessment

1、Standardized Echocardiography Across Diverse Animal Models

Nonclinical safety assessment relies on a wide range of laboratory animal species, placing high demands on the adaptability of imaging equipment, examination protocols, and data acquisition methodologies across different models.

To address these requirements, InnoStar has established a comprehensive multi-species echocardiography platform capable of performing standardized cardiac ultrasound evaluations across commonly used laboratory animal species, including mice, rats, guinea pigs, rabbits, beagle dogs, cynomolgus monkeys, and miniature pigs. This broad species coverage supports the diverse animal models routinely utilized in nonclinical safety assessment programs.

By implementing standardized imaging procedures and consistent evaluation criteria across species, the platform enables the generation of reliable and comparable cardiac structure and function data to support drug safety evaluation throughout the development process.

2、Customized SOPs Designed for Species-Specific Anatomical and Physiological Characteristics

Differences in cardiac anatomy, body size, and physiological parameters across animal species require tailored imaging strategies to ensure consistent image quality and data reliability. To address these challenges, InnoStar has established species-specific standard operating procedures (SOPs) for echocardiographic evaluation.

Non-Human Primates and Beagle Dogs

For larger animal species such as cynomolgus monkeys and beagle dogs, appropriate transducer configurations and imaging parameters are selected to facilitate high-quality visualization of deeper cardiac structures. Animals are typically examined in the right lateral recumbent position, enabling comprehensive assessment of cardiac morphology and function.

Rodents

For rodents such as Sprague-Dawley (SD) rats, high-frequency ultrasound transducers are utilized to accommodate the unique challenges associated with small body size, rapid heart rates, and superficial cardiac anatomy. Under inhalation anesthesia support, animals are positioned in dorsal recumbency to ensure stable image acquisition and consistent data quality throughout the examination.

3、Advanced Imaging Technology Supporting High-Quality Data Acquisition

High-quality imaging data are fundamental to reliable cardiovascular safety assessment. InnoStar utilizes advanced digital color Doppler ultrasound systems designed to support life science research, providing high-resolution cardiac imaging and robust image acquisition capabilities across a wide range of animal models.

Combining detailed two-dimensional (2D) imaging with color Doppler flow imaging technologies, the platform enables comprehensive visualization of cardiac morphology and hemodynamics. These capabilities support the quantitative assessment of cardiac chamber structure, ventricular function, and blood flow parameters, helping generate reliable data for nonclinical safety evaluation.

03

Rigorous Quality Control: Standardized Measurement Practices and Extensive Historical Data Resources

Echocardiographic assessment depends not only on the performance and precision of imaging equipment, but also heavily on the technical expertise of operators during examinations under anesthesia and the rigor of data processing. Together, these factors form the foundation for ensuring the reliability of nonclinical safety assessment data.

*Highly Standardized Measurement Protocols

Using left ventricular function assessment as an example, operators are required to accurately acquire the right parasternal long-axis four-chamber view and perform measurements in M-mode according to a predefined eight-point measurement protocol. This rigorous standardization minimizes operator-dependent variability and ensures data comparability across study phases and experimental batches, providing reliable support for nonclinical safety assessment programs.

*An Industry-Leading Species-Specific Reference Database

A robust historical database is fundamental to the consistency and reliability of cardiovascular assessments. Through years of standardized operations, InnoStar has established comprehensive reference databases for major laboratory animal species and has systematically evaluated their stability and applicability.

For example, in beagle dogs—one of the most commonly used nonclinical models—InnoStar has accumulated complete echocardiographic datasets from nearly 200 animals, covering key cardiac functional parameters such as heart rate, ejection fraction (EF), and fractional shortening (FS).

Based on this validated reference database, our team can define the normal range of biological variation for individual parameters and more effectively identify potential cardiovascular risk signals during study evaluations. This resource not only reflects InnoStar’s technical expertise but also provides a reliable reference framework that supports the reproducibility, consistency, and accuracy of study results.

*Real-World Project Experience: Standardized Detection of Potential Cardiovascular Risk Signals

In practical applications, this validated echocardiographic evaluation system has repeatedly demonstrated its ability to detect drug-related cardiovascular risk signals.

In one repeat-dose toxicity study, serial echocardiographic assessments were conducted at predefined time points in accordance with established SOPs, allowing dynamic monitoring of cardiac function parameters throughout the study. This approach enabled the timely detection of transient changes in cardiac function in certain animals following dosing, providing important evidence for the early identification of potential cardiovascular liabilities.

In another representative case involving unexpected mortality in individual animals, longitudinal and comparable echocardiographic data enabled the team to reconstruct the progression of cardiac functional changes over time, providing valuable imaging evidence to support cause-of-death investigations and mechanistic interpretation.

Because imaging views, measurement locations, and assessment time points were standardized throughout the study, subtle changes in cardiac function could be consistently detected even under complex experimental conditions and interpreted in conjunction with other study findings. These project experiences demonstrate that the value of echocardiography extends beyond identifying abnormalities; it also provides high-quality and reproducible data that support cardiovascular safety evaluation and risk interpretation during drug development.

04

Capturing Subtle Cardiac Changes Through Advanced Echocardiographic Assessment

The integration of echocardiography and nonclinical safety assessment forms a key component of InnoStar’s cardiovascular safety evaluation capabilities. Supported by advanced imaging systems, comprehensive multi-species coverage, standardized operating procedures, and extensive historical reference databases, InnoStar has established a robust cardiovascular ultrasound imaging platform to support reliable cardiac safety assessment throughout drug development.

Whether supporting routine toxicology studies, repeat-dose toxicity evaluations, or dedicated cardiovascular safety programs, our team is committed to delivering high-quality imaging data and scientifically sound interpretations to help identify and evaluate potential cardiovascular risks.

If your cardiovascular safety assessment program requires echocardiographic support, we welcome the opportunity to discuss how InnoStar can support your nonclinical development needs.